NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Kura Oncology, Inc.
Dana-Farber Cancer Institute
University of Colorado, Denver
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
BlossomHill Therapeutics